At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Marek Trn?ný (Charles University Hospital, Prague, Czech Republic) discusses the phase 2 SPRINT (MCL-002) study of lenalidomide versus investigators choice in relapsed or refractory mantle cell lymphoma, including the study design; efficacy and safety endpoints; and conclusions.
This programme has been supported by sponsorship from Celgene